Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study Jason 
AbstrACt
Interventions Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and reimbursed as a third-line therapy for patients with advanced NSCLC by the Taiwan National Health Insurance ( Conclusions The changes in reimbursement policies had a significant impact on the accessibility of targeted therapies for NSCLC treatment. Removing reimbursement restrictions can significantly increase the level and the speed of drug accessibility.
IntrODuCtIOn
Lung cancer is the leading cause of cancer deaths worldwide. About 85% of all lung cancers are identified as non-small cell, and approximately 75% of these are metastatic or advanced at diagnosis, for which no curative treatment is available. [4] [5] [6] [7] Since 2004, oral targeted therapies for non-small cell lung cancer (NSCLC) have been launched in the market for patients with epidermal growth factor receptor (EGFR) mutation in Taiwan. Two targeted drugs, gefitinib and erlotinib, were first approved as third-line therapy for patients with advanced NSCLC by the Taiwan Food and Drug Administration, based on results of randomised clinical trials. [8] [9] [10] For patients with advanced NSCLC with mutation-positive EGFR, two drugs were further suggested to be used as strengths and limitations of this study ► Both prescription rate and speed (time to prescription) were used to measure drug accessibility. ► An interrupted time-series design, a strong quasi-experimental method, was applied. ► A segmented linear regression model was used to estimate postpolicy changes in both the level and trend of these study outcomes. ► Data from the claims' database of the Taiwan National Health Insurance research Database were analysed that did not cover data for payments made by the patients themselves.
Open access first-line therapy by the recent National Comprehensive Cancer Network guideline, 11 as a result of the cumulative evidence showing a significant association between mutated EGFR and because of their clinical benefits. 8 12-14 According to 'Directions for Drug Restricted Benefits for National Health Insurance', gefitinib and erlotinib have been reimbursed for the treatment of lung cancer in Taiwan since 2004 and 2007, respectively. When reimbursement for gefitinib by the health insurance began in November 2004, considering the potential significant impact of its use on the healthcare drug expenditure budget, its use was limited only to patients with NSCLC who had previously used platinum and docetaxel or paclitaxel chemotherapy, but who still partially progressed or metastasised (for the third-line treatment). Later, clinical studies have confirmed that the efficacy and safety of gefitinib are better than those for chemotherapy drugs, and that clinical treatment guidelines are recommended for second-line treatment. To improve the accessibility of drugs and early use of new drugs, in November 2007, the Taiwan National Health Insurance (NHI) began to pay for gefitinib as a second-line treatment for patients who had previously used first-line platinum-containing chemotherapy, or patients 70 years of age or older who had received first-line chemotherapy but were still partially exacerbated or metastatic. 14 15 Finally, because clinical studies have confirmed that the efficacy of first-line therapy is better than that of posterior therapy, gefitinib has been further allowed to be used as a first-line therapy for patients with EGFR mutation-positive advanced NSCLC since June 2011. 12 16 17 Similarly, erlotinib's use was limited for a third-line treatment in the begining (June 2007), and it has been further allowed to be used as a first-line therapy for patients with EGFR mutation-positive advanced NSCLC since June 2013. [18] [19] [20] [21] [22] Little is known about the impacts of changes in targeted therapy-related reimbursement policies (related to removing reimbursement restrictions and broadening the eligible patient population) in Taiwan. The aim of our longitudinal analyses was to address this gap by examining the recent trends in utilisation of and expenditures for targeted therapies (gefitinib and erlotinib) following changes in the reimbursement policy, which involve the accessibility and economic burden of drugs. Furthermore, we also evaluated the changes in time to prescription of NSCLC over time.
MethOD

Data sources
All monthly claims data, including prescription details and insurer spending, for antineoplastic agents between 2004 and 2013 were retrieved from Taiwan's National Health Insurance Research Database (NHIRD). The database contains information from a nationwide, mandatory-enrolment, single-payer healthcare system created in 1995. Nearly 99% of the Taiwanese population (around 23 million residents) is enrolled, and this system contracts with 97% of hospitals and clinics throughout the country. The NHI covers a wide range of prescription medicines as well as inpatient and outpatient medical services. 23 NSCLC-related prescriptions were identified using the International Classification of Diseases, Ninth Revision diagnosis codes for cancer (codes: 162). Patients with small cell lung cancer and patients who had used etoposide and topotecan were not included in the study.
Drugs of interest
We used the Anatomical Therapeutic Chemical (ATC) Classification System from WHO. We identified all antineoplastic agents using the ATC code 'L01'. Targeted therapies included in the analysis were protein kinase inhibitors (gefitinib and erlotinib). New targeted therapies (afatinib, crizotinib and ceritinib) were not included in this study because they were not reimbursable by NHI prior to 2013.
Measurements
To examine the trends in the accessibility of targeted therapies (gefitinib and erlotinib) following the changes in reimbursement policies, we calculated the monthly number of patients who used each targeted therapy and the related costs from 2004 to 2013. Then, we estimated the proportion of their use by patient number and the market share by cost among total patient numbers and total costs of all antineoplastic agents. The prescribing rate of the targeted therapies by patient number was estimated by using the number of patients who had used the targeted therapies divided by the number of patients who had used antineoplastic agents, and the market share of targeted therapies by cost was estimated by using the cost of the targeted therapies divided by the cost of antineoplastic agents. The cost was adjusted using the yearly Consumer Price Index (CPI). 24 
statistical analysis
The interrupted time series design, 25 a strong quasi-experimental method, was adopted to evaluate the overall changes in drug utilisation (prescribing rate and market share of cost) before and after the four modifications to the drug reimbursement policy: (1) For average time to prescription, we combined the previous three policy changes as one intervention due to the fact that their timing was similar.
A segmented linear regression model was used to estimate postpolicy changes in both the level and trend of these study outcomes. [26] [27] [28] [29] Using baseline trends, we projected rates over time with the assumption that the baseline trend reflected what would have happened without the implementation of the promotion strategies. The basic model included terms to estimate the baseline level for each outcome (intercept) (β 0 ), baseline trend Open access (slope) (β 1 ), changes in the level immediately after policy implementation (β 2 ) and changes in the trend after the policy change (β 3 ) (see the following model). 25 30 Our models also controlled for autocorrelation. 31 To identify the most parsimonious models, we used backward elimination and excluded non-significant terms (p>0.05).
Y t = β 0 + β 1 * time t + β 2 * intervention t + β 3 * time_after_ intervention t + e t 25 To summarise the results as a single metric, we expressed policy intervention by using the relative difference between the actual value and the predicted value after the policy intervention, and we estimated the relative changes in the prescription rates and market shares (with 95% CIs) 32 in outcomes 3 months following the interventions compared with projected rates. We calculated the relative change by using this formula: relative change = (actual value − predicted value) in outcomes 3 months following the interventions/predicted value in outcomes 3 months following the interventions.
In addition, we selected patients who had used the targeted therapies during the study period, and based on the time of newly diagnosed NSCLC, time to prescription was used to represent the length of time required before use of the targeted therapies (representing the speed of drug accessibility). We also calculated the average of the difference between diagnosis date and the date of first use of the targeted therapies for each year over time. The relative changes of the average time to prescription (with 95% CIs) 32 in outcomes 2 years following the interventions compared with projected rates were estimated. The relative changes were calculated using the following formula: relative change = (actual value − predicted value) in outcomes 2 years following the interventions/ predicted value in outcomes 2 years following the interventions. All analyses were carried out with SAS software, V.9.4 (SAS Institute, Cary, North Carolina, USA).
Patient and public involvement
Patients were not involved in this study.
results Prescribing rate of targeted therapies by patient number Claims data for a total of 92 220 patients with NSCLC were collected. Table 1 Market share of targeted therapies by cost During the 10-year study period, the estimated market share of targeted therapies by cost increased from Figure 1 (C) shows the prescribing rate of erlotinib by patient number over time.
There was a relative reduction of 30 (table 3) . It dropped substantially by 234.37% after erlotinib was covered by NHI, and gefitinib/erlotinib became available as second-line treatments, but it did not change after gefitinib became available as a first-line treatment (table 4) .
DIsCussIOn
Drug accessibility, especially the accessibility of expensive drugs that target cancer, has become the favourite topic of analysis of drug utilisation. [33] [34] [35] Although some highly priced drugs have been approved for marketing, the reimbursement restriction from health insurance is an obstacle to drug accessibility. 36 37 In this study, the data from NHIRD were used to examine the utilisation of targeted therapies for NSCLC during 2004-2013 (10 years). Using a strong quantitative research method (an interrupted time-series design), our findings revealed changes in the accessibility of the targeted therapies, including the prescribing rate, prescription speed and economic burden, following a series of reimbursement policy modifications.
It was found that four interventions had significant effects on the use of gefitinib and erlotinib. To understand the impacts of the drug reimbursement policy of 'removing reimbursement restrictions and broadening the eligible patient population', the prescribing rate and Open access Table 2 Estimated changes in targeted therapies utilisation following changes in reimbursement policies using segmented regression models Relative changes = (actual value − predicted value) in outcomes 3 months following the interventions/predicted value in outcomes 3 months following the interventions NA, not available; NHI, National Health Insurance; NS, not significant.
Open access prescription speed were used to represent the accessibility of drugs. The results made it possible to determine whether 'removing reimbursement restrictions and broadening the eligible patient population' actually allowed more patients to have access to targeted therapies. In the case of gefitinib, the prescribing rate has steadily risen since it was first covered by NHI in 2004. Then, the coverage of erlotinib (as a third-line treatment) for NSCLC resulted in a drop in gefitinib by 20% (prescribing rate) and 6% (market share by expenditure). A few months later, availability of gefitinib as a second-line treatment resulted in the greatest changes in gefitinib use (a 54.32% increase). When erlotinib became available as a secondline treatment, gefitinib's use reduced by 13%. Then, gefitinib's prescribing rates and expenditures rose again (a 21% increase in prescribing rate and a 17% increase in expenditures) when gefitinib became available as firstline treatment.
In the case of erlotinib, three changes in reimbursement rules had significant effects on prescribing rates and market share by cost. Especially, after gefitinib became available as a second-line treatment, the prescribing rate and market share of cost decreased by 27% and 30%, respectively. In addition, the previous rates of erlotinib reduced by 10% and 9%, respectively, after gefitinib became available as a first-line treatment. On the other hand, when erlotinib became available as a second-line treatment, approximately 23% and 22% increases in prescribing rates and market share by cost were observed, respectively.
The overall use of oral targeted therapies (gefitinib and erlotinib) did not rise following the introduction of erlotinib in June 2007. However, their use significantly rose by 15% when gefitinib became available as a second-line treatment in November 2007, while it fell by 10% when erlotinib became available as a second-line treatment in June 2008. When gefitinib became available as a first-line treatment, the overall prescription rate of oral targeted therapies only increased by 6%. On the other hand, the market share of cost of oral targeted therapies was only slightly diminished when erlotinib became available as a second-line treatment in June 2008, but it was not affected by other interventions. In general, these changes in the reimbursement rules were effective with regard to improving the accessibility of the targeted therapies.
As for the speed of accessibility of the targeted therapies related to NSCLC treatment, the average time to prescription for targeted therapies gradually reduced from 802 days in 2004 to 43 days in 2013. This means the changes in the reimbursement rules (removing reimbursement restriction and broadening the eligible patient population) markedly accelerated the accessibility of the targeted therapies.
Past research indicates that the accessibility of a drug is related to the health insurance coverage proportion. 37 38 This study used the accessibility of the targeted therapy for NSCLC treatment; for example, it further proved that in health insurance, removing reimbursement restrictions can significantly increase the accessibility of drugs and the speed of accessibility of drugs. Although the accessibility of drugs has increased through changes in health insurance policies, healthcare resource allocation and health inequalities between various cancer types or diseases are issues that need to be subsequently followed up.
This study has several limitations. First, the study focused on the effects of removing reimbursement Open access restrictions and broadening the eligible patient population in relation to the accessibility of medicines. We used three indicators: prescribing rate, market share of cost and time to prescription, as measurements of accessibility of medicine. Due to the lack of clinical test data in the Taiwan NHIRD claims database, this study was not able to identify patients' eligibility to obtain the targeted therapies based on clinical testing (such as pathology or cytological results and EGFR gene mutation test results, etc). Second, in this study, data from the Taiwan NHIRD claims database were analysed; these data did not cover data for payments made by the patients themselves. Hence, there may be differences between the estimated prescription rate/costs and the actual value. However, this gap is not believed to be very significant since the proportion of payments made by patients themselves was very small. Third, considering the timing of drug launches, during the study period (2004-2013), only two first-generation targeted therapies (gefitinib and erlotinib) could be included, and newer medicines were out of the scope of this study. Finally, this study was aimed towards an examination of the effects of removing reimbursement restrictions and broadening the eligible patient population related to accessibility to the targeted therapies. In future there is a need for further studies on how such policies affect the clinical outcomes of treatments and the cost-effectiveness of the policies.
COnClusIOn
The present study examined how multiple, separate changes in reimbursement policies have changed drug utilisation and accessibility of the targeted therapies. Overall, removing reimbursement restrictions and broadening the eligible patient population for NSCLC-targeted therapies improved the accessibility of such medications. In detail, when a targeted therapy became available for either early or broad use, utilisation increased, but this Relative changes = (actual value − predicted value) in outcomes 2 years following the interventions/predicted value in outcomes 2 years following the interventions NA, not available; NHI, National Health Insurance; NS, not significant.
Open access
may have, in turn, decreased the use of other similar classes of drugs. In addition, the targeted therapies were prescribed faster once their insurance reimbursement restrictions were lifted. The results of this study can be used as the empirical basis for clinical treatment, to help enhance the content of academic literature on this subject, and can serve as the empirical basis for future targeted therapy studies.
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